Are anti-anxiety medications, such as benzodiazepines (e.g. alprazolam (Xanax)) and non-benzodiazepines (e.g. buspirone (Buspar)), legal and available by prescription in European countries for individuals with anxiety disorders?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 1, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Anti-Anxiety Medications Are Legal and Available by Prescription Throughout Europe

Anti-anxiety medications, including both benzodiazepines (such as alprazolam/Xanax) and non-benzodiazepines (such as buspirone/Buspar), are legal and available by prescription in all European countries for the treatment of anxiety disorders. 1

Evidence from European Medical Practice

The availability of these medications across Europe is clearly documented in current medical guidelines:

  • Hydroxyzine is explicitly approved for anxiolytic use in Europe (as well as the United States), available in both tablet and syrup formulations with few contraindications. 1

  • Benzodiazepines such as midazolam are widely used in some European countries for medical procedures, including pediatric imaging, demonstrating their legal status and clinical availability. 1

  • European medical facilities routinely use benzodiazepines for anxiolysis, sedation, and pain management according to hospital and national regulations, with administration performed by authorized, qualified personnel. 1

Classes of Anti-Anxiety Medications Available

Benzodiazepines

  • Alprazolam (Xanax), lorazepam, diazepam, and other benzodiazepines are legal prescription medications used for generalized anxiety disorder, panic disorder, social anxiety disorder, and separation anxiety disorder. 1, 2

  • These medications work rapidly, with alprazolam producing improvement within the first week of treatment in clinical trials. 2

Non-Benzodiazepine Anxiolytics

  • Buspirone (Buspar) is an FDA-approved anxiolytic that is chemically and pharmacologically unrelated to benzodiazepines, barbiturates, or other sedative/anxiolytic drugs. 3

  • Buspirone has demonstrated efficacy comparable to benzodiazepines for treating generalized anxiety disorder, though it produces more gradual improvement over 2-4 weeks rather than immediate effects. 4, 2

SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

  • Venlafaxine and duloxetine are available for anxiety disorders, with duloxetine having FDA indication specifically for generalized anxiety disorder in children and adolescents aged 7 years and older. 1

  • These medications are as efficacious as SSRIs in treating anxiety with comparable tolerability. 5

Important Prescribing Considerations

Duration of Use

  • Benzodiazepines should be prescribed for the shortest duration possible, ideally 2-4 weeks maximum, as approximately 50% of patients prescribed benzodiazepines continuously for 12 months develop dependence. 6, 7

  • Continuing prescriptions beyond 4 weeks without re-evaluation dramatically increases dependence risk. 6

Safety Profile Differences

  • Buspirone lacks the sedation, anticonvulsant, and muscle-relaxant properties of benzodiazepines, and does not cause psychomotor impairment when combined with alcohol or given alone. 4

  • Buspirone has shown no abuse, dependence, or withdrawal symptoms in clinical studies, making it a safer long-term option. 4

  • Benzodiazepines carry risks of dependence, tolerance, withdrawal symptoms (including seizures), cognitive impairment, and falls, particularly in elderly patients. 6, 7

Common Pitfall to Avoid

Do not assume that anti-anxiety medications are restricted or illegal in Europe. The evidence clearly demonstrates these medications are part of standard medical practice across European healthcare systems, prescribed according to established clinical guidelines and national regulations. The key distinction is not legality, but rather appropriate prescribing practices that emphasize short-term benzodiazepine use and consideration of non-benzodiazepine alternatives like buspirone or SNRIs for longer-term anxiety management. 1, 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Qualitative review of SNRIs in anxiety.

The Journal of clinical psychiatry, 2004

Guideline

Benzodiazepine Discontinuation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Benzodiazepine Selection and Use for Psychiatric Conditions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What medication should be tried next for chronic stress and anxiety if buspirone (Selective Serotonin Receptor Partial Agonist) is not effective?
What are the risks and benefits of combining Buspar (buspirone) and Alprazolam (Xanax) for generalized anxiety disorder?
What is the best initial dose of buspirone (anxiolytic medication) for generalized anxiety disorder in a 30-year-old woman?
What are the treatment options for anxiety in a bipolar patient allergic to buspirone (Buspar) who is currently taking lamotrigine (Lamictal) 200mg and aripiprazole (Abilify) 10mg?
What is the next best step for a 67-year-old patient with anxiety and panic attacks causing suicidal ideation (SI), currently taking Xanax (alprazolam) 0.25 mg as needed (PRN) and buspirone (at a dose of 30 mg, 8 times a day, every 3 hours, instead of prescribed 7.5 mg four times a day), with potential SSRI (selective serotonin reuptake inhibitor) activation and increased SI?
What is the best approach to manage proctitis in a patient with fecal impaction, considering treatment options and potential complications?
What are the guidelines for treating influenza in high-risk patients?
Can Candida antibodies be tested for in a patient suspected of having a Small Intestine Fungal Overgrowth (SIFO) infection?
What is the most appropriate next step in management for an elderly patient with a history of ischemic stroke, who recently underwent major surgery, and now presents with shortness of breath, chest pain, and a confirmed Deep Vein Thrombosis (DVT)?
What is the management and treatment for a 41-year-old male with hypertension, dyslipidemia, type 2 diabetes, obesity, sleep apnea, chronic kidney disease (CKD), and hepatic steatosis, admitted for syncope with ventricular ectopic beats, transient ventricular nonsustained tachycardia, and atrial fibrillation?
What is the optimal therapy for a patient with hemorrhagic stroke, particularly with regards to blood pressure management and prevention of further bleeding?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.